pi4kb

T-00127_HEV1 is an inhibitor of phosphatidylinositol 4-kinase III beta (IC50: 60 nM).

PI4Kβ-IN-1 is an orally active selective inhibitor of PI4Kβ with an IC50 of 0.9 nM. It exhibits inhibitory activity across all stages of the P. falciparum lifecycle, including the blood, liver, and transmission phases. In mouse models infected with Plasmodium falciparum, PI4Kβ-IN-1 demonstrates significant antimalarial efficacy. This compound is applicable for research on malaria caused by Plasmodium falciparum.

Pipinib is an ATP-competitive and selective phosphatidylinositol 4-kinase IIIβ (PI4KB) inhibitor with an IC50 value of 2.2 μM. Pipinib reduces intracellular PI4P levels and inhibits GLI-mediated transcription as well as the expression of Hedgehog target genes. Pipinib additionally blocks the trafficking of Smoothened to primary cilia. Pipinib is applicable to investigations involving basal cell carcinoma, medulloblastoma, Hedgehog signaling, and phosphoinositide-associated cellular regulation.

GSK-A1 is a specific inhibitor of PI4KA, also inhibited calcium-driven PRL secretion without affecting calcium signaling and Prl expression. GSK-A1 has anti-hepatitis C virus (HCV) potential.

Torin 2(IC50=0.25 nM), a specific and effective mTOR inhibitor, is the 800-fold greater specific activity for mTOR than PI3K and improves pharmacokinetic properties. The EC50 of Torin 2 for ATM/ATR/DNA-PK inhibition is 28 nM/35 nM/118 nM, respectively.

Necrosulfonamide ((E)-Necrosulfonamide) is a necroptosis inhibitor that targets MLKL and is selective. Necrosulfonamide prevents the MLKL-RIP1-RIP3 necrosomal complex from interacting with its downstream effectors.

PI4K-IN-2 (Compound 30) is a highly selective inhibitor of type III phosphatidylinositol 4-kinase beta (PI4KB) with an IC50 value of 0.015 μM. It holds potential for research in human rhinovirus (HRV).